Argentina Expands Access To Meds With Public Production
Argentina is pushing forward with plans to expand access to medicines by driving public production.
You may also be interested in...
High inflation, a drop in the price of its commodities and restrictions on imports have not made for a good economic environment in Argentina and have proved a turnoff for investors. But a general election is around the corner and there are hopes that a new administration may set things right. So with change blowing in the wind, companies with flagging pipelines should consider what Argentina has to offer, not least a rich R&D community that helped create the world's first ever cancer vaccine against non-small cell lung cancer, and a vibrant local industry open to partnerships .
Brazil is to manufacture its own version of Janssen's monoclonal antibody Remicade (infliximab), thanks to a technology transfer deal with Janssen worth R$206mn ($80mn), says the health ministry.
Industry access to real world data for regulatory and market access purposes in Asia Pacific compares poorly with the US.